SLIDE 1
www.escardio.org
2
European Heart Journal 2015 doi/10.1093/eurheartj/ehv316
management of patients with ventricular arrhythmias and the - - PowerPoint PPT Presentation
management of patients with ventricular arrhythmias and the - - PowerPoint PPT Presentation
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
SLIDE 2
SLIDE 3
www.escardio.org
The 2015 ESC Guidelines for the management of VA and prevention of SCD
- To describe and explain the epidemiology and pathophysiology of
ventricular arrhythmias and SCD
- To provide an up-to-date summary on current knowledge but also –
and even more important – of current knowledge gaps
- To come up with the best consensus on available and reasonable
diagnostics and therapies
- To provide practical and clinical help to identify patients at risk for
ventricular arrhythmia and sudden cardiac death.
- To guide the management of VA and SCD and thereby promoting
the best outcome to improve quality of life and reduce the burden of SCD
- To raise further awareness on the global threat of SCD.
3
SLIDE 4
II AOP 100
SLIDE 5
II AOP 100
SLIDE 6
www.escardio.org
Autopsy and molecular autopsy in sudden death victims
- ~ 50% of cardiac arrests occur in individuals without known heart
disease, but most suffer from concealed ischaemic heart disease.
- Every time a heritable disease is identified in a deceased individual,
the relatives may be at risk of being affected and dying suddenly.
6
SLIDE 7
www.escardio.org
Diagnostic workup in patients presenting with sustained ventricular tachycardia or ventricular fibrillation
SLIDE 8
www.escardio.org
Diagnostic workup in patients presenting with sustained ventricular tachycardia or ventricular fibrillation
8
Speaker
SLIDE 9
www.escardio.org
Diagnostic workup in patients presenting with sustained ventricular tachycardia or ventricular fibrillation
9
Speaker
SLIDE 10
www.escardio.org
Therapies for ventricular arrhythmias
- Pharmacotherapy for VA and prevention of SCD
- With the exception of beta-blockers, currently
available AAD have not been shown in RCT to be effective in primary management of patients with life-threatening VA or in prevention of SCD.
- Each drug has a significant potential for causing
adverse events, including pro-arrhythmia.
10
SLIDE 11
www.escardio.org
Antiarrhythmic drugs for the prevention of SCD
amiodaron vs. Placebo ICD therapie vs. Placebo HR 97.5% CI P-value 1.06 0.86, 1.30 0.53 0.77 0.62, 0.96 0.007
follow-up (months)
12 24 36 48 60 0.1 0.2 0.3 0.4
mortality
amiodaron placebo ICD Bardy GH, N Engl J Med 2005
SLIDE 12
www.escardio.org
Primary prevention of SCD with the ICD
SLIDE 13
www.escardio.org
The subcutaneous ICD
SLIDE 14
www.escardio.org
- Device therapy - Subcutaneous cardioverter defibrillator
- SC defibrillators are effective in preventing SD.
- Data on long-term tolerability and safety are currently lacking.
- The device is not suitable for patients who require bradycardia
pacing, CRT or those who suffer from tachyarrhythmias that can be easily terminated by ATP.
14
SLIDE 15
www.escardio.org
- Device therapy - Wearable cardioverter defibrillator
- No prospective randomized trials evaluating the device have been
reported.
- Many case reports, case series, & registries (held by manufacturer
- r independently) have reported successful use of WCD in a
relatively small proportion of patients at risk of potentially fatal VAs.
15
SLIDE 16
www.escardio.org
Diagnostic workup in patients with sustained ventricular arrhythmias and ACS.
16
SLIDE 17
www.escardio.org
Sustained VT in structural heart disease: drugs or ablation?
SLIDE 18
www.escardio.org
Sustained ventricular tachycardia
- Drug therapy
18
- Catheter ablation
SLIDE 19
www.escardio.org
Catheter ablation of ventricular tachycardia
SLIDE 20
www.escardio.org
Interventional therapy - Catheter ablation
- Scar-related VT - typically monomorphic.
- 12-lead ECG recording of clinical VT can aid ablation procedure.
- VT related to post-myocardial scar - better outcome of catheter ablation
than VT due to non-ischaemic CMP.
- Procedure-related mortality ranges from 0% - 3%.
- VT in patients without overt structural heart disease most commonly from
RVOT or LVOT.
- Catheter ablation - high rate of procedural success; rate of SCD generally low.
20
SLIDE 21
www.escardio.org
Outfow tract ventricular arrhythmias
RVOT/PA LVOT/AO CS/EPI AP AP LL TA PV MV AV CS GCV
*
*
*
* **
Tanner et al., JACC 2005
SLIDE 22
www.escardio.org
VT and VF in structurally normal hearts
- Outflow tract ventricular tachycardia
22
SLIDE 23
www.escardio.org
Catheter ablation of ventricular fibrillation
Haissaguerre M et al. Lancet 2002; 359:677–678
SLIDE 24
www.escardio.org
Idiopathic ventricular fibrillation
24
Short-coupled torsade de pointes
SLIDE 25
www.escardio.org
Drug-related pro-arrhythmia
- Should be suspected if an inherited or acquired arrhythmogenic
substrate has been excluded and patient is treated with agents known to alter electrical properties of the heart (e.g. inducing QT prolongation) or causing electrolyte abnormalities.
25
SLIDE 26
www.escardio.org
To do and to not do messages
26
SLIDE 27
www.escardio.org
27
ESC Pocket Guidelines application available!
European Heart Journal 2015 doi/10.1093/eurheartj/ehv316